Contract Pharma Staff05.04.20
Kindeva Drug Delivery, formerly 3M Drug Delivery Systems, has launched as an independent company following its acquisition by Altaris Capital Partners in a transaction valued at $650 million. As part of the transaction, 3M will retain a 17% minority interest in Kindeva alongside Altaris.
Kindeva is a global contract development and manufacturing organization (CDMO) that specializes in solving complex drug delivery challenges for its pharmaceutical and biotechnology customers. With approximately 900 employees, Kindeva serves customers with expertise in formulation, product development, and manufacturing.
Kindeva-developed and manufactured therapies treat patients battling a host of debilitating and chronic diseases, including respiratory illnesses and cardiovascular conditions. The company’s microneedle-based drug delivery platforms are currently being utilized in dozens of development programs, including programs for osteoporosis, immunotherapies, COVID-19 vaccines, and other difficult-to-deliver therapies. Kindeva holds over 500 active patents and works with clients ranging from large blue-chip pharmaceutical companies to small biotechs.
“Kindeva brings deep expertise to the unique challenges of developing combination products and complex drugs, including those that are playing an important role in the fight against COVID-19,” said Aaron Mann, CEO of Kindeva Drug Delivery. “Over the years, 3M has built a differentiated platform of drug delivery technologies and I look forward to the opportunities ahead for Kindeva as an independent company in partnership with Altaris. We will be executing an ambitious growth plan that involves significant capital investment and the addition of new jobs across our operating regions. This is an exciting time for Kindeva and our talented colleagues.”
Kindeva has cGMP manufacturing operations in Loughborough, UK; Clitheroe, UK; Northridge, CA; and St. Paul, MN; and R&D laboratories in Loughborough and St. Paul. Products manufactured by Kindeva are distributed to over 60 countries worldwide.
Kindeva is a global contract development and manufacturing organization (CDMO) that specializes in solving complex drug delivery challenges for its pharmaceutical and biotechnology customers. With approximately 900 employees, Kindeva serves customers with expertise in formulation, product development, and manufacturing.
Kindeva-developed and manufactured therapies treat patients battling a host of debilitating and chronic diseases, including respiratory illnesses and cardiovascular conditions. The company’s microneedle-based drug delivery platforms are currently being utilized in dozens of development programs, including programs for osteoporosis, immunotherapies, COVID-19 vaccines, and other difficult-to-deliver therapies. Kindeva holds over 500 active patents and works with clients ranging from large blue-chip pharmaceutical companies to small biotechs.
“Kindeva brings deep expertise to the unique challenges of developing combination products and complex drugs, including those that are playing an important role in the fight against COVID-19,” said Aaron Mann, CEO of Kindeva Drug Delivery. “Over the years, 3M has built a differentiated platform of drug delivery technologies and I look forward to the opportunities ahead for Kindeva as an independent company in partnership with Altaris. We will be executing an ambitious growth plan that involves significant capital investment and the addition of new jobs across our operating regions. This is an exciting time for Kindeva and our talented colleagues.”
Kindeva has cGMP manufacturing operations in Loughborough, UK; Clitheroe, UK; Northridge, CA; and St. Paul, MN; and R&D laboratories in Loughborough and St. Paul. Products manufactured by Kindeva are distributed to over 60 countries worldwide.
